

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Cardboard box (10 ml, 5 x 10 ml, 6 x 10 ml)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Mepivacaine Richter 20 mg/ml solution for injection for horses

Mepivacaine hydrochloride

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:

Mepivacaine hydrochloride 20 mg
(equivalent to 17.4 mg mepivacaine)

3. PHARMACEUTICAL FORM

Solution for injection

4. PACKAGE SIZE

10 ml
5 x 10 ml
6 x 10 ml

5. TARGET SPECIES

Horse

6. INDICATION(S)

Read the package leaflet before use.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For intra-articular and epidural use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal period(s):
Meat and offal: 3 days
Milk: 72 hours

9. SPECIAL WARNING(S), IF NECESSARY

Pregnant women should avoid handling the product.

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}
Once broached use immediately.

11. SPECIAL STORAGE CONDITIONS

Protect from light.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.
Any remaining contents after use should be discarded.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

VetViva Richter GmbH, Durisolstrasse 14, 4600 Wels, Austria

16. MARKETING AUTHORISATION NUMBER

Vm 57446/4009

17. MANUFACTURER’S BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

10 ml clear glass vial type I with bromobutyl rubber stopper and alu-caps

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Mepivacaine Richter 20 mg/ml solution for injection for horses

Mepivacaine hydrochloride

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

20 mg/ml

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

10 ml

4. ROUTE(S) OF ADMINISTRATION

For intra-articular and epidural use.

5. WITHDRAWAL PERIOD(S)

Withdrawal period(s):

Meat and offal: 3 days

Milk: 72 hours

6. BATCH NUMBER

Lot {number}

7. EXPIRY DATE

EXP {month/year}

Once broached use immediately.

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

B. PACKAGE LEAFLET

7. TARGET SPECIES

Horse

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Full aseptic precautions should be observed when injecting the product.

For intra-articular anaesthesia: 60-600mg of mepivacain hydrochloride (3 to 30 ml of the medicinal product), dependent on joint size

For epidural use: 0.2 – 0.25 mg/kg (1.0 to 1.25 ml/100 kg), up to 10 ml/horse, depending on the depth and extent of anaesthesia required.

In all instances the dosage should be kept to the minimum required to produce the desired effect. The duration of action is about 1 hour. It is recommended that the skin should be shaved and thoroughly disinfected prior to the intra-articular or epidural administration.

This product does not contain an antimicrobial preservative. Use the vial on one occasion only. Discard any unused material.

9. ADVICE ON CORRECT ADMINISTRATION

See section 12. "Special warnings".

10. WITHDRAWAL PERIOD(S)

Meat and offal: 3 days

Milk: 72 hours

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Keep the vial in the outer carton in order to protect from light.

This veterinary medicinal product does not require any special temperature storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after "EXP". The expiry date refers to the last day of that month.

Shelf life after first opening the container: Use immediately

12. SPECIAL WARNING(S)

Special warnings for each target species:

None

Special precautions for use in animals:

Aspirate prior to and during administration to avoid intra-vascular injection.

The analgesic effect of mepivacaine, when used as part of a lameness investigation, begins to subside after 45-60 minutes. However, sufficient analgesia may persist to affect gait beyond two hours.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to mepivacaine or other local anaesthetics of the amide group should avoid contact with the product.

This product may be an irritant to the skin and eyes.

Avoid contact with the skin and eyes. Wash any splashes from skin and eyes immediately with plenty of water. Seek medical advice if irritation persists.

Adverse effects on the foetus cannot be excluded. Pregnant women should avoid handling the product.

Accidental self-injection may result in cardiorespiratory and/or CNS effects. Care should be taken to avoid accidental self-injection. In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician. Do not drive.

Wash hands after use.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Mepivacaine crosses the placenta. There is no evidence that mepivacaine is associated with reproductive toxicity or teratogenic effects.

However, there is a potential for anaesthetics of the amide group such as mepivacaine to accumulate in the equine foetus resulting in neonatal depression and interfering with resuscitation efforts. Therefore, use in obstetric anaesthesia only according to the benefit/risk assessment of the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

Mepivacaine should be used carefully in patients undergoing treatment with other local anaesthetics of the amide group since the toxic effects are additive.

Overdose (symptoms, emergency procedures, antidotes):

Symptoms related to overdose correlate with symptoms occurring after inadvertent intravascular injection as described in section "Adverse reactions".

Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with any other veterinary medicinal products.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.


14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

July 2023

15. OTHER INFORMATION

Pack sizes: 10 ml, 5 x 10 ml, 6 x 10 ml.
Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

A handwritten signature in black ink, consisting of several loops and a final flourish.

Approved: 28 July 2023